- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Brian A. Bohnenkamp
News 4 results
Recognition
June 15, 2020
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2020 Guide
Recognition
April 24, 2020
King & Spalding Earns Top Rankings in Chambers USA 2020 Guide
In the News · Source: P&T Community
April 11, 2019
Brian Bohnenkamp discusses the Trump Administration's changes to rebates for pharmacy rebate managers
Press Release
November 5, 2015
King & Spalding Elects 24 New Partners
Events 6 results
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Speaking Engagement
August 6, 2020
Seth Lundy, Brian Bohnenkamp, Gina Cavalier, Terrence Burek to Speak on Webinar About Compliance in the Time of COVID
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Conference
September 5, 2019
12th Annual Medical Device Summit
Insights 19 results
Client Alert
February 3, 2021
Implementation of Final Rule Excluding PBM Rebates from Discount Safe Harbor Delayed Until 2023
Feature
January 15, 2021
General Counsel Internal Investigations Decision Tree for the Life Sciences Industry
Client Alert
November 25, 2020
HHS Finalizes Rule Challenging Drug Manufacturer Rebates to PBMs and Payors
Client Alert
November 24, 2020
Are Pharma Speaker Programs Facing an Existential Crisis?